Page last updated: 2024-08-18

thiophenes and thienopyridine

thiophenes has been researched along with thienopyridine in 50 studies

Research

Studies (50)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	26 (52.00)	29.6817
2010's	24 (48.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adang, AE; Draaijer, J; Hanssen, RG; Schoonus-Gerritsma, GG; Timmers, CM; van Boeckel, CA; van Someren, RG; van Straten, NC	1
Asai, F; Jakubowski, JA; Niitsu, Y; Sugidachi, A	1
Antman, EM; Behounek, BD; Braunwald, E; Carney, RJ; Lazzam, C; McCabe, CH; McKay, RG; Murphy, SA; Weerakkody, G; Winters, KJ; Wiviott, SD	1
Bliden, KP; Gurbel, PA; Tantry, US	1
Huber, K; Schrör, K; Siller-Matula, J; Wojta, J	1
Blair, PE; Farid, NA; Gillespie, TA; Goldberg, MJ; Kurihara, A; Rash, TJ; Smith, RL	1
Farid, NA; Hagihara, K; Ikeda, T; Kawabata, K; Kawai, K; Kazui, M; Kurihara, A; Takahashi, M	1
Ali, ZS; Carling, D; Heath, R; Hegarty, BD; Sanders, MJ; Snowden, MA	1
Ernest, CS; Farid, NA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ	1
Klauss, V; Krötz, F; Sohn, HY	1
Conn, PM; Dias, JA; Huhtaniemi, IT; Janovick, JA; Maya-Núñez, G; Ulloa-Aguirre, A; Verbost, P	1
Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ	1
Cairns, JA; Eikelboom, J	1
Farid, NA; Hagihara, K; Ikeda, T; Kazui, M; Kurihara, A; Nishiya, Y	1
Baize, AL; Engstrom, KM; Franczyk, TS; Kallemeyn, JM; Mulhern, MM; Rickert, RC; Wagaw, S	1
Das, K; Das, P; Koshy, SK; Robinson, A	1
Makarov, LM; Serebruany, VL	1
Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A	1
Wallentin, L	1
Kumar, A; Roberts, DH	1
Berntsson, P; Björkman, JA; van Giezen, JJ; Zachrisson, H	1
Dobesh, PP	1
Farid, NA; Hagihara, K; Honda, K; Ikeda, T; Kazui, M; Kurihara, A; Okazaki, O; Yoshiike, M	1
Kastrati, A; Sibbing, D	1
Antman, EM; Bates, ER; Braunwald, E; Close, SL; Hautvast, RW; Mega, JL; Michelson, AD; Murphy, SA; O'Donoghue, ML; Rozenman, Y; Sabatine, MS; Shen, L; Ver Lee, PN; Wiviott, SD	1
Farid, NA; Kurihara, A; Wrighton, SA	1
Jilma, B; Krumphuber, J; Siller-Matula, JM	1
Solomon, S; Vacek, JL	1
Islam, AM; Patel, PM	1
Farid, NA; Hagihara, K; Ikeda, T; Ishikawa, M; Iwabuchi, H; Kazui, M; Kobayashi, H; Kurihara, A; Okazaki, O; Tanaka, N	1
Chew, DP; Prakash, R; Wong, YW	1
Gurbel, PA; Mahla, E; Metzler, H; Tantry, US	1
Aly, HM; Elhady, HA; Saleh, NM	1
Li, Y; Ma, Z; Wang, F; Wang, J; Wang, Y	1
Abtan, J; Aubry, P; Barthélémy, O; Belle, L; Beygui, F; Boueri, Z; Carrié, D; Cayla, G; Collet, JP; Cuisset, T; Elhadad, S; Henry, P; Kerneis, M; Monségu, J; Montalescot, G; Motreff, P; O'Connor, SA; Pouillot, C; Rangé, G; Rousseau, H; Sabouret, P; Saint-Etienne, C; Silvain, J; Van Belle, E; Vicaut, E	1
Fareed, J; Jeske, W; Thethi, I	1
Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Chakrabarti, AK; Cohen, M; Gibson, CM; Goto, S; Mega, J; Mohanavelu, S; Stone, G; Verheugt, FW	1
Beigel, R; Elian, D; Fefer, P; Fink, N; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Rosenberg, N; Segev, A	1
Angiolillo, DJ; Braun, OÖ; Costigan, TM; Duvvuru, S; Effron, MB; Ferreiro, JL; Jakubowski, JA; Kleiman, NS; Saucedo, JF; Sundseth, S; Varenhorst, C; Walker, JR; Winters, KJ	1
Chua, D; Nishi, C	1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; White, HD	1
Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Price, MJ	1
Hartung, P; Hill, K; Schaefer, M; Schulze, A	1
Allocco, DJ; Christen, T; Garratt, KN; Jenkins, RG; Kereiakes, DJ; Lee, DP; Mauri, L; Pow, TK; Weaver, WD; Winters, KJ	1
Lee, BH; Lim, CJ; Oh, KS; Oh, SA; Yi, KY	1
Chen, L; Liu, D; Liu, Y; Tao, Z; Xia, G; Zhi, S	1
Al-Dosari, MS; Al-Mishari, AA; Almoqbil, AN; Alsaid, MS; Ghorab, MM; Ragab, FA	1
Gaikwad, N; Kalvala, AK; Kumar, A; Madhavi, YV; Nanduri, S; Yerra, VG	1

Reviews

15 review(s) available for thiophenes and thienopyridine

Article	Year
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:2 Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Biotransformation; Clinical Trials, Phase I as Topic; Clopidogrel; Collagen; Drug Evaluation, Preclinical; Drug Synergism; Fibrinolytic Agents; Hemostasis; Humans; Male; Membrane Proteins; Molecular Structure; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombin; Thrombosis; Ticlopidine	2005
Prasugrel. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:12 Topics: Adenosine Diphosphate; Animals; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Collagen; Coronary Disease; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2006
Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thrombosis and haemostasis, 2007, Volume: 97, Issue:3 Topics: Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resistance; Drugs, Investigational; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2007
Antiplatelet drugs in cardiological practice: established strategies and new developments. Vascular health and risk management, 2008, Volume: 4, Issue:3 Topics: Atherosclerosis; Clopidogrel; Drug-Eluting Stents; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thromboxane; Signal Transduction; Thiophenes; Thrombosis; Ticlopidine	2008
Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. Future cardiology, 2009, Volume: 5, Issue:3 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2009
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. European heart journal, 2009, Volume: 30, Issue:16 Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine	2009
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (London, England), 2009, Sep-19, Volume: 374, Issue:9694 Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome	2009
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. Journal of clinical pharmacology, 2010, Volume: 50, Issue:2 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2010
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. British journal of pharmacology, 2010, Feb-01, Volume: 159, Issue:3 Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor	2010
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy. Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:6 Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Thrombosis; Ticlopidine	2010
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Current opinion in cardiology, 2010, Volume: 25, Issue:4 Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2010
Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. The Annals of thoracic surgery, 2010, Volume: 90, Issue:3 Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticlopidine	2010
Metabolic differences of current thienopyridine antiplatelet agents. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:3 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Fibrinolytic Agents; Hemorrhage; Humans; Inactivation, Metabolic; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine	2013
New antiplatelet agents for cardiovascular disease. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Nov-05, Volume: 185, Issue:16 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Targeting AMPK in Diabetes and Diabetic Complications: Energy Homeostasis, Autophagy and Mitochondrial Health. Current medicinal chemistry, 2019, Volume: 26, Issue:27 Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Biological Products; Biphenyl Compounds; Diabetes Complications; Diabetes Mellitus; Energy Metabolism; Humans; Hypoglycemic Agents; Mitochondria; Pyridines; Pyrones; Thiophenes	2019

Trials

12 trial(s) available for thiophenes and thienopyridine

Article	Year
Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation, 2005, Jun-28, Volume: 111, Issue:25 Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; Male; Membrane Proteins; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2005
The disposition of prasugrel, a novel thienopyridine, in humans. Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:7 Topics: Administration, Oral; Biotransformation; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Cysteine; Feces; Humans; Hydrolysis; Intestinal Absorption; Male; Methylation; Molecular Structure; Oxidation-Reduction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Pyridines; Reference Values; Tandem Mass Spectrometry; Thiophenes	2007
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. Journal of clinical pharmacology, 2008, Volume: 48, Issue:1 Topics: Adolescent; Adult; Area Under Curve; Bupropion; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Delayed-Action Preparations; Drug Interactions; Half-Life; Humans; Male; Middle Aged; Molecular Structure; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Pyridines; Tandem Mass Spectrometry; Thiophenes; Time Factors	2008
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. Journal of the American College of Cardiology, 2008, Dec-09, Volume: 52, Issue:24 Topics: Adult; Aged; Clopidogrel; Comorbidity; Coronary Artery Disease; Diabetes Complications; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Pyridines; Thiophenes; Ticlopidine; Treatment Failure; Treatment Outcome	2008
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683 Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Myocardial Infarction; Proportional Hazards Models; Pyridines; Recurrence; Risk Reduction Behavior; Rivaroxaban; Safety; Statistics, Nonparametric; Stroke; Thiophenes; Treatment Outcome	2009
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary. Postgraduate medicine, 2010, Volume: 122, Issue:1 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2010
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22 Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Retreatment; Stents; Thiophenes; Ticlopidine	2012
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. Journal of the American College of Cardiology, 2013, Jul-23, Volume: 62, Issue:4 Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stents; Thiophenes; Thrombosis; Treatment Outcome	2013
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Thrombosis and haemostasis, 2013, Volume: 110, Issue:6 Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Blood Platelets; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Activation; Polymorphism, Genetic; Prasugrel Hydrochloride; Prospective Studies; Pyridines; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. European heart journal, 2014, Volume: 35, Issue:4 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Female; Humans; Kaplan-Meier Estimate; Male; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin	2014
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification. Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:4 Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Receptors, Purinergic P2Y12; Reproducibility of Results; ROC Curve; Sensitivity and Specificity; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement. Circulation, 2015, Jan-06, Volume: 131, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Incidence; Internationality; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Time Factors; Treatment Outcome	2015

Other Studies

23 other study(ies) available for thiophenes and thienopyridine

Article	Year
The first orally active low molecular weight agonists for the LH receptor: thienopyr(im)idines with therapeutic potential for ovulation induction. Chembiochem : a European journal of chemical biology, 2002, Oct-04, Volume: 3, Issue:10 Topics: Administration, Oral; Animals; CHO Cells; Cricetinae; Estradiol; Female; Humans; Leydig Cells; Male; Mice; Molecular Weight; Ovulation Induction; Ovum; Pyridines; Pyrimidines; Receptors, FSH; Receptors, LH; Testosterone; Thiophenes	2002
Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats. Xenobiotica; the fate of foreign compounds in biological systems, 2007, Volume: 37, Issue:7 Topics: Animals; Carbon Radioisotopes; Intestinal Absorption; Male; Piperazines; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Rats, Inbred F344; Thiophenes	2007
Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. The Journal of biological chemistry, 2007, Nov-09, Volume: 282, Issue:45 Topics: AMP-Activated Protein Kinases; Biphenyl Compounds; Cell Line; Enzyme Activation; Humans; Multienzyme Complexes; Mutation; Phosphorylation; Protein Binding; Protein Serine-Threonine Kinases; Protein Subunits; Pyridines; Pyrones; Thiophenes; Threonine	2007
Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine. Molecular and cellular endocrinology, 2009, Jan-27, Volume: 298, Issue:1-2 Topics: Animals; Cell Membrane; Chlorocebus aethiops; COS Cells; Dose-Response Relationship, Drug; Humans; Models, Biological; Protein Binding; Protein Transport; Pyridines; Pyrimidines; Receptors, FSH; Receptors, LH; Thiophenes; Transfection	2009
The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy. Journal of the American College of Cardiology, 2008, Dec-09, Volume: 52, Issue:24 Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticlopidine; Treatment Failure	2008
Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug metabolism and pharmacokinetics, 2008, Volume: 23, Issue:6 Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Oxidoreductases, N-Demethylating; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2008
Improved synthesis of 3-substituted-4-amino-[3,2-c]-thienopyridines. The Journal of organic chemistry, 2009, May-15, Volume: 74, Issue:10 Topics: Carbon Dioxide; Cyclization; Halogens; Metals; Oxidation-Reduction; Pyridines; Thiophenes	2009
Future of oral antiplatelet therapy: four challenged hypotheses. Thrombosis and haemostasis, 2009, Volume: 101, Issue:6 Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Prognosis; Purinergic P2 Receptor Antagonists; Pyridines; Risk Assessment; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2009
Test before you stop. Archives of surgery (Chicago, Ill. : 1960), 2009, Volume: 144, Issue:8 Topics: Adenosine; Algorithms; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2009
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thrombosis research, 2009, Volume: 124, Issue:5 Topics: Adenosine; Animals; CHO Cells; Clopidogrel; Cricetinae; Cricetulus; Disease Models, Animal; Dogs; Hemostasis; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine; Transfection	2009
Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy, 2009, Volume: 29, Issue:9 Topics: Absorption; Blood Platelets; Dose-Response Relationship, Drug; Half-Life; Humans; Metabolic Clearance Rate; Molecular Structure; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Time Factors	2009
A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug metabolism and disposition: the biological fate of chemicals, 2009, Volume: 37, Issue:11 Topics: Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Humans; Microsomes, Liver; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2009
Risk of combining PPIs with thienopyridines: fact or fiction? Lancet (London, England), 2009, Sep-19, Volume: 374, Issue:9694 Topics: Biotransformation; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Pyridines; Thiophenes; Ticlopidine	2009
Clinical trial update II: TRITON-TIMI 38 provides reassurance on concomitant use of proton pump inhibitors and thienopyridines. European heart journal, 2009, Volume: 30, Issue:23 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:6 Topics: Biotransformation; Humans; Nitrobenzoates; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Sulfhydryl Compounds; Thiophenes	2010
Design and synthesis of some new thiophene, thienopyrimidine and thienothiadiazine derivatives of antipyrine as potential antimicrobial agents. European journal of medicinal chemistry, 2011, Volume: 46, Issue:9 Topics: Anti-Infective Agents; Drug Design; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Pyridines; Spectrophotometry, Infrared; Thiadiazines; Thiophenes	2011
Rivaroxaban (Xarelto) for acute coronary syndrome. The Medical letter on drugs and therapeutics, 2011, Dec-12, Volume: 53, Issue:1379-1380 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration	2011
Structural requirements of pyrimidine, thienopyridine and ureido thiophene carboxamide-based inhibitors of the checkpoint kinase 1: QSAR, docking, molecular dynamics analysis. Journal of molecular modeling, 2012, Volume: 18, Issue:7 Topics: Binding Sites; Checkpoint Kinase 1; Hydrogen Bonding; Molecular Dynamics Simulation; Protein Conformation; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrimidines; Quantitative Structure-Activity Relationship; Thiophenes	2012
Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction. The American journal of cardiology, 2013, Nov-15, Volume: 112, Issue:10 Topics: Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine; Treatment Outcome	2013
Transient receptor potential ankyrin 1 (TRPA1) channel activation by the thienopyridine-type drugs ticlopidine, clopidogrel, and prasugrel. Cell calcium, 2014, Volume: 55, Issue:4 Topics: Calcium; Calcium Channels; Cell Line; Clopidogrel; Enterochromaffin-like Cells; Gene Expression Regulation; HEK293 Cells; Humans; Mutation; Nerve Tissue Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Serotonin; Thiophenes; Ticlopidine; Time-Lapse Imaging; Transient Receptor Potential Channels; TRPA1 Cation Channel	2014
Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists. Bioorganic & medicinal chemistry letters, 2014, Dec-15, Volume: 24, Issue:24 Topics: Animals; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Microsomes, Liver; Protein Binding; Pyridines; Rats; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Thiophenes; Urea	2014
Synthesis of the alkylated active metabolite of tipidogrel. Bioorganic & medicinal chemistry letters, 2015, Apr-15, Volume: 25, Issue:8 Topics: Alkylation; Animals; Chromatography, High Pressure Liquid; Clopidogrel; Half-Life; Piperidines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Tandem Mass Spectrometry; Thiophenes; Ticlopidine	2015
Novel quinolines carrying pyridine, thienopyridine, isoquinoline, thiazolidine, thiazole and thiophene moieties as potential anticancer agents. Acta pharmaceutica (Zagreb, Croatia), 2016, Jun-01, Volume: 66, Issue:2 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Female; Humans; Inhibitory Concentration 50; Isoquinolines; MCF-7 Cells; Models, Molecular; Molecular Structure; Pyridines; Quinolines; Structure-Activity Relationship; Thiazoles; Thiazolidines; Thiophenes	2016